Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2014-01-28 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2014-01-28 English
FORM 3 -
Director's Dealing
2014-01-24 English
THERAVANCE, INC. 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 13, 2014, reporting the appointment of a Senior Vice President, Operations. The content focuses on management changes, including details about the new appointee's background, compensation, and agreements. There are no financial statements or detailed financial performance data. The document is not an annual or quarterly report, nor is it an earnings release or audit report. It clearly fits the category of announcements related to changes in the company's board or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters, but it is not merely an announcement of a report publication; it is the actual announcement of a management change.
2014-01-23 English
FORM 3 -
Director's Dealing
2014-01-17 English
THERAVANCE, INC. 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing, which is a current report pursuant to the Securities Exchange Act of 1934. It announces the launch of a product (Relvar Ellipta) in Germany and provides details about the product and its indications. There is no financial data, earnings information, or detailed report content. The document is short (2996 characters) and serves as an announcement of a corporate event rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2014-01-13 English
THERAVANCE, INC. 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a press release about the approval of a drug in Canada, which is an event announcement rather than a financial report or detailed filing. The document length is 3086 characters, which is relatively short and includes a press release as an exhibit. There is no financial data, management discussion, or detailed report content. Therefore, this is a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like earnings release or capital update.
2014-01-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.